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Summary
Loss of bone and muscle mass are two major clinical complications among the growing list of 
chronic diseases that primarily affect elderly individuals. Persistent low-grade inflammation, one 
of the major drivers of aging, is also associated with both bone and muscle dysfunction in aging. 
Particularly, chronic activation of the receptor for advanced glycation end products (RAGE) and 
elevated levels of its ligands high mobility group box 1 (HMGB1), AGEs, S100 proteins and Aβ 
fibrils have been linked to bone and muscle loss in various pathologies. Further, genetic or 
pharmacologic RAGE inhibition has been shown to preserve both bone and muscle mass. 
However, whether short-term pharmacologic RAGE inhibition can prevent bone and muscle early 
loss in aging is unknown. To address this question, we treated young (4-mo) and middle-aged (15-
mo) C57BL/6 female mice with vehicle or Azeliragon, a small-molecule RAGE inhibitor initially 
developed to treat Alzheimer’s disease. Azeliragon did not prevent the aging-induced alterations in 
bone geometry or mechanics, likely due to its differential effects [direct vs. indirect] on bone cell 
viability/function. On the other hand, Azeliragon attenuated the aging-related body composition 
changes [fat and lean mass] and reversed the skeletal muscle alterations induced with aging. 
Interestingly, while Azeliragon induced similar metabolic changes in bone and skeletal muscle, 
aging differentially altered the expression of genes associated with glucose uptake/metabolism in 
these two tissues, highlighting a potential explanation for the differential effects of Azeliragon on 
bone and skeletal muscle in middle-aged mice. Overall, our findings suggest that while short-term 
pharmacologic RAGE inhibition did not protect against early aging-induced bone alterations, it 
prevented against the early effects of aging in skeletal muscle.
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1. Introduction
Due to the drastic advances in healthcare over the last several decades, people are now living 
longer than ever before. Paradoxically, this has created a new clinical challenge, i.e. a vast 
array of chronic degenerative diseases, including heart disease, cancer, diabetes, 
neurodegeneration, often accompanied by the development of debilitating conditions, such 
as sarcopenia and osteoporosis (Franceschi et al., 2018; Khosla, Farr, & Kirkland, 2018; 
Rodier, Zhou, & Ferbeyre, 2018). To combat these pathologies of aging, there has been 
growing interest in geroscience, a research field focused on identifying/targeting common 
biological mechanisms that drive aging and underlie aging-related pathologies (Franceschi et 
al., 2018; Seals, Justice, & LaRocca, 2016). Recent advancements in this field have 
identified several common key risk factors, such as chronic-low grade inflammation, cellular 
senescence, metabolic dysfunction, macromolecular damage, genomic instability, reduced 
responsiveness to stress and altered proteostasis, associated with numerous of these 
‘comorbidities of aging’ (Gerakis & Hetz, 2018; Howcroft et al., 2013; Khosla et al., 2018; 
Rodier et al., 2018; Seals et al., 2016).
However, to date, most work has focused primarily on the mechanisms underlying 
cardiovascular disease, cancer and neurodegeneration; whereas, the mechanisms underlying 
debilitating aging-related conditions, such as sarcopenia and osteoporosis, have been less 
studied. Given the skyrocketing number of individuals with osteoporosis [affecting ~1:2 
women of all ages, and ~1:4 men over age 50 and costing the US ~$25.3 billion a year in 
healthcare expenses (Abrahamsen, van Staa, Ariely, Olson, & Cooper, 2009; Fischer et al., 
2017)] and the increasing incidence of sarcopenia [affecting ~13% of Americans over age 55 
and costing the US ~$18.5 billion a year in related-health expenses (Sousa et al., 2016; 
Tournadre, Vial, Capel, Soubrier, & Boirie, 2018)], there is an essential need to better 
understand the mechanisms leading to musculoskeletal pathology.
Further, considering the growing evidence showing the interconnected relationship between 
bone and skeletal muscle (Collins et al., 2018; Karsenty & Mera, 2018; Reginster, Beaudart, 
Buckinx, & Bruyere, 2016), and the fact that most elderly patients with bone and muscle 
loss are also affected by other aging-related comorbidities (Agostini et al., 2018; Franceschi 
et al., 2018), there is a crucial need to identify therapeutics capable of simultaneously 
targeting and treating multiple pathologies.
Low-grade chronic inflammation is one factor identified as a key driver of numerous aging-
related pathologies (Amarasekara, Yu, & Rho, 2015; Ramasamy, Shekhtman, & Schmidt, 
2016). Various cell types release inflammatory cytokines, which not only regulate immune 
response, but also modulate key cellular processes: differentiation, proliferation, apoptosis, 
and autophagy throughout the organism (Amarasekara et al., 2015; Heneka et al., 2015; 
Ramasamy et al., 2016). In particular, emerging evidence suggests that inflammatory 
cytokine signaling plays a role in regulating bone and skeletal muscle metabolism under 
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both physiological and pathological conditions (Bidwell, Yang, & Robling, 2008; Karsenty 
& Mera, 2017). Consistently, chronic low-grade inflammation has been identified as a major 
contributor of dysfunction in both musculoskeletal tissues in aging (Andersson, Yang, & 
Harris, 2018; Fougere, Boulanger, Nourhashemi, Guyonnet, & Cesari, 2017; Picca et al., 
2017).
Particularly, elevated RAGE [receptor for advanced glycation end-products] signaling has 
been shown to contribute to the onset/progression of various aging-related pathologies 
(Cardoso et al., 2018; Ramasamy et al., 2016). RAGE is a multi-ligand pattern recognition 
receptor, which binds and mediates the cellular response to a range of endogenous damage-
associated molecular pattern molecules (DAMPs) including advance glycation end-products 
(AGEs), high mobility group box 1 (HMGB1), S100 proteins, Aβ fibrils, and DNA/RNA 
(Lee & Park, 2013; Sorci, Riuzzi, Giambanco, & Donato, 2013). Under physiological 
conditions, RAGE is expressed at low levels, but during conditions of chronic inflammation 
RAGE is upregulated due to the accumulation of its ligands (Ramasamy et al., 2016; Sorci et 
al., 2013).
Numerous studies have demonstrated beneficial effects with RAGE inhibition [genetic and 
pharmacological] in various aging-related pathologies including diabetes, cardiovascular 
disease, neurodegeneration, and cancer (Schmidt, 2015). Further, downregulation of RAGE 
signaling has been shown to protect against disease-induced bone and muscle loss. 
Particularly, in bone, genetic RAGE deficiency prevented against OVX induced bone loss in 
mice; and consistently, blockade of cellular RAGE using soluble RAGE diminished alveolar 
bone loss in a murine model of diabetic periodontal disease (Ding et al., 2006; Lalla et al., 
2000). Additionally, in skeletal muscle, young mice fed a diet high in AGEs exhibited 
impaired skeletal muscle growth and contractile function (Egawa et al., 2017). Interestingly, 
AGEs were found to induce skeletal muscle atrophy by stimulating RAGE-mediated AMPK 
down-regulation, an effect that was attenuated in RAGE-deficient mice (Chiu et al., 2016). 
Moreover, high intracellular levels of RAGE ligand, S100B, known to inhibit myogenic 
differentiation by repressing the myogenic regulatory factors MyoD and myogenin, were 
detected in muscle satellite cells isolated from aged subjects (Tubaro, Arcuri, Giambanco, & 
Donato, 2010). Taken together, these pieces of evidence highlight the potential involvement 
and the therapeutic opportunity to target/inhibit RAGE signaling during the onset/
progression of bone and muscle pathology in aging.
Small-molecule RAGE inhibitors have been developed and their therapeutic utility has been 
evaluated in pre-clinical and clinical studies over the last decade (Bongarzone, Savickas, 
Luzi, & Gee, 2017). For example, TTP488 (Azeliragon, AZ), a small-molecule compound 
that prevents RAGE from binding to AGEs, HMGB1, S100 proteins, and Aβ fibrils (Fig. 
1A), has been evaluated for the treatment of Alzheimer’s disease in pre-clinical and clinical 
studies (Galasko et al., 2014; Panza et al., 2016; Walker, Lue, Paul, Patel, & Sabbagh, 2015). 
However, whether pharmacological inhibition of RAGE affects bone and muscle in young 
individuals, and whether it attenuates the loss of bone and muscle mass in aging is not 
known. In this study we examined the possibility of repurposing the Alzheimer’s drug, AZ, 
to prevent aging-induced osteoporosis and sarcopenia. Here we report that while RAGE 
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inhibition does not attenuate the effects of aging on bone, it mitigates the effects of aging on 
skeletal muscle.
2. Results
2.1 AZ differentially alters bone metabolism through direct and indirect actions.
To test the effects of pharmacological RAGE inhibition using the small-molecule inhibitor, 
AZ (Fig. 1A), on osteoclast differentiation, we first treated wildtype non-adherent bone 
marrow cells (BMC) isolated from 4-month-old (young) or 16-month-old (middle-aged) 
C57BL/6 female mice (JAX® Mice, 2017) with vehicle (veh) or AZ in vitro. Consistent 
with previous findings in global genetic RAGE knockout mice (Zhou & Xiong, 2011), a 
lower number of mature osteoclasts (≥3 nuclei) developed from young or middle-aged 
BMCs treated with AZ (Fig. 1B). Further, more osteoclast were developed when cells were 
isolated from middle-aged mice. Based on these findings, we next investigated the in vivo 
effects of systemic AZ administration on osteoclast differentiation/activity and whether it 
prevents bone loss in early aging. To this end we treated female wild type C57BL/6 4-
month-old (young) and 15-month-old (middle-aged) mice daily with AZ (~4μg/g) or veh for 
28 days (Fig. 2A).
Bone histomorphometric analysis of veh-treated mice revealed no alterations in osteoclast 
number (N.Oc/BS) or surface (Oc.S/BS) per bone surface on the femur endocortical or 
vertebral cancellous bone surfaces (Fig. 2B,C) with aging, although, vertebral cancellous 
osteoclast number per tissue area (N.Oc/T.Ar) was lower in middle-aged compared to young 
veh-treated mice. Further, vertebral cancellous bone perimeter (B.Pm) was decreased in the 
middle-aged compared to young mice (Fig. 2C). Vertebral cancellous osteoclast number per 
tissue area (N.Oc/T.Ar) was lower in middle-aged compared to young veh-treated mice. 
Consistently, osteoclast gene expression was significantly decreased (Fig. 2D) and serum 
bone resorption marker, C-terminal telopeptide (CTX), levels were lower in middle-aged 
compared to young veh-treated mice (Fig. S1).
Consistent with the in vitro findings, static histomorphometric analysis revealed that AZ 
treatment in young and middle-aged mice significantly reduced the number of osteoclasts on 
the vertebral cancellous and femoral cortical bone surfaces (Fig. 2B,C). However, the 
decreased vertebral osteoclast parameters appear to be a result of increases in vertebral 
cancellous B.Pm, rather than decreases in N.Oc/BS or Oc.S/BS since N.Oc was not changed 
in the AZ-treated mice (Fig. 2C). Likewise, AZ treatment did not alter the expression of any 
osteoclast-related genes in the tibia, aside from an increase in calcitonin receptor (Fig. 2D). 
Further, we were surprised to find that serum CTX levels were higher in the AZ-treated mice 
at both ages (Fig. S1), suggesting that more bone surfaces are being resorbed in the presence 
of AZ.
We next examined the effects of aging and AZ treatment on osteoblast differentiation and 
function. Histomorphometric analysis revealed that vertebral cancellous osteoblast number 
per tissue area (N.Ob/T.Ar) was significantly decreased in middle-aged compared to young 
veh-treated mice, although due the decreased vertebral cancellous B.Pm in the middle-aged 
mice osteoblast number and surface per bone surface (N.Ob/BS and Ob.S/BS) were 
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unchanged (Fig. 3A). Further, veh-treated middle-aged mice exhibited lower serum bone 
formation marker, pro-collagen type 1 N-terminal propeptide (P1NP) levels (Fig. 3B), and 
gene expression analysis detected similar decreases in mRNA levels for osteoblastic genes 
with aging (Fig. 3C). However, no aging-related changes in mineral apposition rate (MAR), 
mineralizing surface (MS)/BS, or bone formation rate (BFR)/BS were detected by dynamic 
histomorphometric analysis of the vertebral cancellous bone of young and middle-aged veh-
treated mice (Fig. 3D). On the other hand, age-related alterations in bone formation were 
detected on the surfaces of the femur mid-diaphysis (Fig. 3E), suggesting that in the middle-
aged veh-treated control mice only cortical bone formation was altered.
In contrast to the effects of AZ on osteoclasts, the effects on osteoblasts were age-dependent. 
Specifically, while vertebral cancellous osteoblast parameters, N.Ob/T.Ar, N.Ob/BS and 
Ob.S/BS were lower with AZ treatment in mice at both ages, uncorrected N.Ob was only 
lower in the middle-aged AZ-treated mice (Fig. 3A). Consistently, dynamic 
histomorphometric analysis only detected decreases in bone formation in the vertebral 
cancellous and femur mid-diaphysis endocortical bone in the middle-aged, but not young 
AZ-treated mice (Fig. 3D,E). Additionally, in vitro treatment of young and middle-aged 
primary adherent BMCs had age-dependent effects, increasing mineralization in young cells, 
but attenuating mineralization in aged cells (Fig. 3F). On the other hand, systemic in vivo 
AZ treatment decreased serum P1NP levels in both young and aged mice (Fig. 3B). Further, 
osteoblast gene expression was decreased in the tibia with AZ treatment in both ages (Fig. 
3C). Taken together these results suggest that inhibition of RAGE signaling may 
differentially affect osteoblast differentiation/activity, at least on the vertebral cancellous 
surface, in an age-dependent manner.
2.2 Inhibition of RAGE signaling increases osteocyte apoptosis and pro-inflammatory 
cytokine production.
Based on the notion that osteocytes are key regulators of bone turnover and to the idea that 
aging-related reductions in osteocyte viability contribute to bone loss (Jilka & O’Brien, 
2016), we next sought to test the effects of AZ treatment on osteocytes. We first measured 
osteocyte apoptosis in active capase3-stained femur cortical bone cross-sections. Aging did 
not alter the proportion of active capase3 positive apoptotic osteocytes, as found before by 
TUNEL staining (Almeida et al., 2007), but the number of empty lacunae (an indication of 
dying osteocytes) was increased in middle-aged compared to young veh-treated mice (Fig. 
4A). Additionally, osteocyte gene expression was decreased with aging (Fig. 4B), and 
consistent with the decreased osteoclast parameters observed in the middle-aged mice, 
RANKL/OPG gene expression was lower in middle-aged mice compared to young animals 
(Fig. 4C).
AZ treatment did not alter the proportion of active capase3-positive apoptotic osteocytes, but 
significantly increased empty lacunae prevalence in young and middle-aged mice (Fig. 4A). 
Consistently, the expression of the osteocyte genes Sost and DMP1 was decreased with AZ 
treatment in both ages (Fig. 4B), whereas, AZ treatment increased the RANKL/OPG ratio in 
bones from middle-aged mice and led to higher inflammatory cytokine IL-6 and MCP-1 
gene expression in bones from young and middle-aged mice (Fig. 4C). Further, gene 
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expression analysis detected tendencies towards increase in the expression of the apoptosis-
associated genes p27 and Foxo3, and a significant increase in the RANKL/OPG mRNA 
ratio, and in the levels of IL-6 and MCP-1 in ex vivo AZ treated osteocyte-enriched bone 
organ cultures (Fig. 4D–F).
2.3 Short-term systemic RAGE inhibition with AZ treatment does not significantly alter 
bone architecture or mechanical properties.
Dual energy x-ray absorptiometry (DXA) analysis showed that spinal bone mineral density 
(BMD) was significantly decreased with aging, whereas, total and femoral BMD were 
unchanged in the middle-aged compared to young veh-treated mice (Fig. 5A). On the other 
hand, micro-computed tomography (μCT) analysis and 3-point femoral biomechanical 
testing detected the expected changes in bone geometry and mechanics, respectively. 
Specifically, lumbar vertebra and distal femur trabecular BV/TV (bone volume/tissue 
volume) and trabecular number (Tb.N) were decreased, whereas trabecular spacing (Tb.S) 
was increased in the middle-aged mice compared to young veh-treated mice (Fig. 5B,C). In 
addition, femur cortical BA/TA (bone area/ tissue area) was decreased, whereas, polar mean 
moment of inertia (MMI), a measurement of resistance to bending, marrow cavity widening, 
and bone tissue porosity were increased with aging (Fig. 5D). Further, the biomechanical 
properties at the structural and material levels were all decreased in the middle-aged 
compared to young veh-treated mice, with the exception of stiffness, which was increased 
with aging (Table 1).
Consistent with the changes in bone cell differentiation/activity, DXA analysis revealed that 
AZ treatment decreased total and femoral BMD in young and middle-aged mice, without 
affecting spinal BMD (Fig. 5A). However, despite the effects on BMD, no changes in bone 
geometry (trabecular and cortical) or biomechanical properties following systemic short-
term AZ treatment in mice at either age were detected by μCT analysis or 3-point femoral 
biomechanical testing, respectively (Fig. 5B–D and Table 1).
2.4 Systemic RAGE inhibition prevents the loss of lean muscle mass and preserves the 
function of cellular processes required to maintain skeletal muscle homeostasis in aging.
Based on the previous reports that both aging and RAGE signaling alter adipose and skeletal 
muscle mass (Egawa et al., 2017), we next tested the effects of systemic AZ treatment on 
these tissues. As expected, body weight of middle-aged compared to young veh-treated mice 
was increased (Fig. 6A), and body composition was altered, with greater fat mass and lower 
lean mass compared to young veh-treated mice (Fig. 6B). Consistently, gastrocnemius, 
tibialis anterior, and quadriceps mass corrected by body weight were all decreased in the 
middle-aged veh-treated mice (Fig. 6C). Further, gene expression analysis detected 
decreases in the expression of MyoD with aging (Fig. 6D). Moreover, histomorphometric 
analysis of H&E-stained forearm skeletal muscle revealed decreases in the average myofiber 
cross-sectional area (CSA) in middle-aged compared to young veh-treated mice (Fig. 7A,B). 
Interestingly, in vitro treatment of C2C12 myotubes with 5% serum from middle-aged 
compared to young veh-treated mice also reduced average myotube diameter and led to a 
shift towards smaller fibers in the representative histograms of the distribution of myotube 
diameter (Fig. 7C,D), suggesting that circulating serum factors may contribute to aging-
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induced muscle atrophy. Consistent with the increased muscle atrophy, ubiquitinated protein 
levels and expression of the E3 ubiquitin ligases Atrogin-1 and MuRF-1, generally 
overexpressed in conditions associated with muscle atrophy (Lecker et al., 2004; Sandri et 
al., 2004), were increased in the skeletal muscles of middle-aged compared to young veh-
treated mice (Fig. 7E,F).
In young mice, AZ decreased body weight (Fig. 6A), and altered body composition reducing 
the fat mass and increasing lean mass (Fig. 6B). Consistently, gastrocnemius and tibialis 
anterior muscle mass (Fig. 6C), as well as myogenin and MyoD expression, measured in the 
tibialis anterior muscle (Fig. 6D), were increased with AZ treatment. However, quadriceps 
muscle weight was decreased (Fig. 6C) and the level of ubiquitinated proteins appear to 
increase with treatment in the young mice (Fig. 7E). Notably, addition of serum from the 
young AZ-treated mice to C2C12 myotubes also significantly reduced myofiber size and 
histomorphometric analysis of H&E-stained forearm muscle revealed decreases in the 
average myofiber CSA in young AZ-treated mice (Fig. 7B,C).
In middle-aged mice, AZ had similar effects on body composition, reversing the aging-
associated increases in body weight (Fig. 6A), as well as, the alterations in body 
composition by reducing the fat mass and increasing lean mass (Fig. 6B). Further, AZ 
reversed the aging-induced loss of the gastrocnemius, tibialis anterior, and quadriceps 
muscle mass in the middle-aged treated mice (Fig. 6C). Consistently, RAGE inhibition 
increased myogenin expression at both ages, and restored MyoD levels in the middle-aged 
mice (Fig. 6D). Moreover, while AZ did not completely reverse the aging-induced decreases 
in myofiber CSA (Fig. 7B), in vitro treatment of C2C12 myoblasts with serum from the 
middle-aged AZ-treated mice did not result in the decreased myotube diameter that was 
induced by serum from the middle-aged veh-treated mice (Fig. 7C,D).
Consistent with these findings, AZ attenuated the aging-induced increases in ubiquitinated 
protein levels and the mRNA levels of Atrogin-1 (Fig. 7E,F). Further, AZ treatment reversed 
the aging-associated alterations in the expression of genes involved in the regulation of 
skeletal muscle cellular processes. Particularly, autophagy- and mitochondria-related gene 
expression was decreased with aging, and AZ treatment increased expression of these genes 
in young and middle-aged mice (Fig. S2), suggesting that in vivo AZ treatment may protect 
against aging-induced muscle atrophy, in part, by preserving the proper functioning of 
cellular processes normally required to maintain skeletal muscle homeostasis and 
metabolism. On the other hand, while aging increased Atrogin-1 and MuRF-1 levels in bone, 
as previously shown with glucocorticoid administration (Sato et al., 2017), AZ did not block 
these increases (Fig. S3).
2.5 AZ treatment reverses the aging-induced metabolic alterations in skeletal muscle but 
not in bone.
Despite the similar aging-induced loss of bone and muscle mass, the findings from the 
present study reveal that aging differentially alters skeletal muscle and bone metabolism. 
Particularly, gene expression analysis of skeletal muscles from young and middle-aged veh-
treated mice demonstrated that aging decreased glucose transporter (Glut1–4) gene 
expression (Fig. 8A). Further, gene expression of glycolytic enzymes (PGK1, LDHA, 
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PDK1) was decreased with aging, whereas the levels of enzymes involved in the regulation 
of oxidative metabolism (PGC-1α and PPAR-α) were unchanged or showed tendencies 
towards increase with aging in the veh-treated mice (Fig. 8B,C). In contrast, in bone, Glut3 
gene expression was decreased with aging, whereas, Glut1 and Glut2 expression was 
significantly increased and Glut4 was not changed with aging (Fig. 6D). Further, LDHA and 
PGK1 expression was increased with aging, whereas PGC-1α and PPAR-α expression was 
unaltered in bone samples from middle-aged compared to young veh-treated mice (Fig. 
8E,F).
We next examined the effects of AZ treatment on the expression of metabolism-related 
genes in skeletal muscle and bone. In skeletal muscle, AZ increased glucose transporter, 
Glut1, Glut3, and Glut4, gene expression, and led to a tendency towards increase in Glut2 
gene expression in mice at both ages (Fig. 8A). Further, in skeletal muscle PGK1 and LDHA 
expression was increased, while the PGC-1α and PPAR-α expression was unchanged with 
AZ treatment in young and middle-aged mice (Fig. 8B,C). In bone, AZ treatment increased 
Glut1 and Glut3 gene expression and led to a tendency towards increase in Glut2 gene 
expression, while Glut4 was not changed (Fig. 8D). Similarly, LDHA, PGK1, and PGC1α 
expression was increased in bone lysates from AZ-treated mice at both ages (Fig. 8E,F). 
Interestingly, we also found that the mRNA expression of leptin and IGF-1, factors known to 
alter cell metabolism, were also differentially altered with aging in skeletal muscle and bone 
tissue lysates (Fig. S4). However, AZ led to similar decreases in leptin levels in both tissues 
at both ages.
3. Discussion
Inflammation is a complex biological process initiated in many cell types in response to 
various stimuli, which stimulates the secretion of numerous factors and subsequently 
mediates processes such as protective immunity, tissue repair and damage resolution 
(Howcroft et al., 2013). Further, while acute inflammation stimulates repair, chronic-
sustained inflammation leads to progressive damage (Fougere et al., 2017). Particularly, 
chronic low-grade inflammation has been associated with numerous age-related 
degenerative diseases and with related debilitating conditions, such as sarcopenia and 
osteoporosis (Cardoso et al., 2018; Ramasamy et al., 2016). Several potential mechanisms of 
age-associated chronic inflammation have been proposed, including the accumulation 
senescent cells, impaired mitochondrial function, reduced levels of autophagy, and altered 
NF-κB signaling (Fougere et al., 2017; Howcroft et al., 2013), which are also seen in bone 
and skeletal muscle with aging (Bonaldo & Sandri, 2013; Lin et al., 2017).
Consistently, sustained RAGE signaling, a known regulator of NF-κB, has been shown to 
contribute to the onset/progression of various aging-related pathologies (Cardoso et al., 
2018; Ramasamy et al., 2016). Particularly, several pieces of evidence have highlighted the 
potential involvement of elevated RAGE signaling in the onset/progression of bone and 
muscle pathology in aging (Ding et al., 2006; Egawa et al., 2017; Lalla et al., 2000). 
However, given the physiological importance of inflammation, whether blocking RAGE can 
reverse aging-related pathologies, particularly, osteoporosis and sarcopenia, remains 
unknown.
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In this study, we tested the effects of short-term systemic administration of the small-
molecule RAGE inhibitor, AZ, on bone and skeletal muscle in aging using a series of in 
vitro and in vivo experiments. Overall, our findings provide evidence that short-term 
pharmacologic RAGE inhibition has effects on bone and muscle metabolism in young and 
middle-aged mice.
Consistent with previous findings in global genetic RAGE knockout mice 
(Charoonpatrapong et al., 2006; Ding et al., 2006; Zhou et al., 2006), RAGE inhibition by 
AZ treatment decreased osteoclast differentiation in vitro. However, in vivo AZ 
administration suppressed bone remodeling and led to a small but significant decrease in 
BMD in young and middle-aged mice. These findings are consistent with previous studies 
showing that femoral cancellous bone accrual and architecture were decreased, and femur 
osteoblast gene (ALP, Cola1, Runx2, and Osterix) expression was lower in 4-month-old 
RAGE knockout compared to control wildtype mice (Philip et al., 2010). Interestingly, 
despite these cellular changes, bone geometry and strength were maintained. Nevertheless, 
our findings provide further support for the important physiological role of RAGE signaling 
in bone. However, opposed to previous findings in RAGE knockout mice, our results suggest 
that systemic administration of a small-molecule RAGE inhibitor may have both direct and 
indirect effects in bone cells that differentially regulate bone metabolism.
Particularly, the differential in vitro versus in vivo effects of AZ on osteoclasts may be due 
to the increases in cell death and inflammatory cytokine production in osteocytes both in 
vitro and in vivo. Hence, despite the direct inhibitory effects of AZ treatment on osteoclasts, 
the effects of RAGE inhibition in osteocytes may indirectly promote bone resorption. 
Considering previous reports that NF-κB signaling is required for proper osteoclast function 
and that AGE-RAGE mediated activation NF-κB signaling induces osteoclastogenesis 
(Boyce, Xiu, Li, Xing, & Yao, 2015; Zhou & Xiong, 2011) coupled with the known anti-
apoptotic effects of NF-κB signaling (Novack, 2011), inhibition of NF-κB signaling may 
mediate the differential effects of AZ.
Future studies will be designed to examine whether administering a different dose or altering 
the treatment regimen [intermittent vs chronic], previously seen with other therapeutics, 
could optimize the beneficial effects of AZ on bone. For example, depending on the mode of 
administration, intermittent vs chronic, parathyroid hormone (PTH), has anabolic or 
catabolic actions on the skeleton (Silva & Bilezikian, 2015). Notably, the catabolic actions 
of PTH have been shown to be mediated through indirect actions on osteoblasts and 
osteocytes, by modulating RANKL and MCP-1 levels (X. Li et al., 2007; Murrills, 2008; 
Wein & Kronenberg, 2018), both of which were increased by AZ. Further, because the mild 
skeletal phenotype observed in mice receiving AZ could be due to modest changes in 
formation and resorption occurring over a short treatment window, future studies will 
explore the long-term effect of AZ administration.
Previous studies showed that AGEs, HMGB1, APP, and amyloid β are present in bone 
(Plotkin, Essex, & Davis, 2019). However, while the levels of RAGE ligands have been 
shown to increase with age (Amarasekara et al., 2015; Ramasamy et al., 2016), to our 
knowledge, no study evaluated the levels of these ligands in bone with aging. It is possible 
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that a mouse with increased activation of RAGE, such as the models of diabetes or other 
inflammatory conditions with increased levels of RAGE ligands, for example, are needed to 
put in evidence the effect of the RAGE inhibitor in bone.
In contrast to the effects of AZ on bone, we found that treatment reversed the aging-induced 
alterations in body composition, leading to lower fat and higher lean body mass compared to 
veh-treated control mice at both ages. These findings are consistent with recent studies 
demonstrating that RAGE signaling regulates the metabolic and inflammatory response to 
high fat feeding in mice (Song et al., 2014). In this study, genetic RAGE deficiency and 
administration of systemic soluble RAGE, a decoy receptor RAGE isoform, reduced fat 
mass in high fat diet fed mice. Although, despite the beneficial effects of AZ administration 
on the skeletal muscle of middle-aged mice, AZ had differential effects on skeletal muscles 
of young animals. Specifically, while several similar positive effects were detected in the 
tibialis anterior muscle, quadriceps mass was decreased and ubiquitin-mediated protein 
degradation was increased in young AZ-treated mice.
Nevertheless, consistent with the beneficial effects on lean body mass, we found that AZ 
treatment reversed the aging-induced decreases in skeletal muscle mass and attenuated 
several aging-induced changes known to be associated with chronic inflammation, including 
NF-κB signaling, mitochondrial function and autophagy. Specifically, AZ preserved the 
expression of known myogenic regulatory factors, such as myogenin and MyoD, and 
attenuated ubiquitin-mediated protein degradation in the aged mice. Consistently, it has been 
suggested that activation of NF-κB post-transcriptionally reduces the cellular levels of 
MyoD (H. Li, Malhotra, & Kumar, 2008). Further, deletion of the β subunit of the inhibitor 
of NF-κB kinase, IKKβ, reduces inflammation, leading to improved skeletal muscle 
strength, maintained mass, and enhanced regeneration (Van Gammeren, Damrauer, Jackman, 
& Kandarian, 2009).
In addition, AGEs induce skeletal muscle atrophy and dysfunction in diabetic mice via 
RAGE-mediated AMPK-induced downregulation of the Akt pathway (Chiu et al., 2016). In 
this study, Atrogin-1 levels were attenuated following RAGE inhibition and consistent with 
this, Atrogin-1 has been previously shown to directly suppress MyoD expression, inhibiting 
protein synthesis and inducing aging-related skeletal muscle atrophy (Fanzani, Conraads, 
Penna, & Martinet, 2012). Consistently, reports suggest that the association between 
Atrogin-1 and skeletal muscle atrophy may be more related to its inhibitory effects on 
protein synthesis (McLoughlin et al., 2009; Senf, Dodd, & Judge, 2010). Taken together 
these pieces of evidence suggest that in middle-aged mice AZ treatment may restore key 
cellular processes normally involved in the maintenance of skeletal muscle mass by directly 
inhibiting AGE-RAGE signaling or by downregulating NF-κB signaling in the skeletal 
muscle.
However, given the increased myotube diameter in C2C12 cultures exposed to serum from 
middle-aged AZ-treated mice, it is also possible that the observed beneficial effects are due 
to systemic alterations rather than direct effect of AZ in skeletal muscle. Thus, additional 
studies are needed to understand the mechanisms underlying the beneficial effects of 
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systemic AZ treatment on skeletal muscle in middle-aged mice. Additionally, whether AZ 
administration also improves muscle function remains to be elucidated.
Nevertheless, our findings suggest that systemic AZ treatment in middle-aged mice might 
contribute to reverse the derangements observed in the skeletal muscle primarily by 
attenuating the aging-associated metabolic defects and by preventing the effects of AGEs 
and potentially other RAGE ligands. Indeed, our findings that AZ treatment protects against 
the aging-related decreases in skeletal muscle glucose transporter gene expression, are 
consistent with reports that AGEs inhibit insulin actions in skeletal muscle and induce 
interference of glucose uptake (Koopman, Ly, & Ryall, 2014). In particular, AGE-RAGE 
binding induces inflammation, triggering ER-stress and initiating the unfolded protein 
response (UPR), which subsequently promotes nuclear translocation of NF-κB (Anelli & 
Sitia, 2008; Piperi, Adamopoulos, Dalagiorgou, Diamanti-Kandarakis, & Papavassiliou, 
2012). Further, recent work demonstrated that nuclear NF-κB directly binds and represses 
Slc2a4 gene transcription, suppressing GLUT4 expression and disrupting glucose uptake 
(Furuya et al., 2013). Thus, our findings that aging decreased skeletal muscle GLUT4 gene 
expression, an effect reversed by AZ administration, suggest that systemic RAGE inhibition 
reverses the aging-induced alterations in skeletal muscle glucose uptake, potentially by 
blocking AGE actions on skeletal muscle.
Further, AZ treatment reversed the aging-induced declines in the expression of skeletal 
muscle glycolytic, but not oxidative metabolism enzymes, which is consistent with reports 
that NF-κβ activation primarily induces fast-twitch, glycolytic muscle fiber atrophy (Wang 
& Pessin, 2013). However, despite the findings that AZ treatment had similar effects on 
glucose transporter and glycolytic enzyme gene expression in bone, aging had opposite 
effects on their expression in bone and skeletal muscle. Altogether, these findings suggest 
that aging differentially affects glucose uptake and metabolism in the different tissues, which 
highlights a potential mechanism underlying the differential effects of AZ treatment on bone 
and skeletal muscle in aging.
In conclusion, our study suggests that short-term pharmacologic RAGE inhibition has 
distinct effects on bone and muscle metabolism. Thus, while AZ treatment did not attenuate 
the aging-induced alterations in bone, it did rescue some of the changes in skeletal muscle. 
In particular, our data points towards a role of RAGE signaling in promoting 
musculoskeletal derangements associated with aging, thus making it an interesting 
therapeutic target. Altogether, our findings strongly support that idea that AZ may represent 
a novel therapeutic option for the treatment of the effects of aging on skeletal muscle.
4. Experimental Procedures
4.1 Osteoclastogenesis assay
Non-adherent BMCs (6×104 cells/cm2) were plated on a 96-well plate with α-minimal 
essential medium (MEM) supplemented with 10% FBS and 1% penicillin/streptomycin 
(P/S) plus recombinant murine M-CSF (20 ng/ml) and soluble RANKL (80 ng/ml) 
(PeproTech Inc., Rocky Hill, NJ, USA) with either 100ng/mL AZ or veh. Media was 
changed every 2 days for 7 days (Davis et al., 2017). Mature osteoclasts (>3 or more nuclei) 
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were quantified after staining for TRAPase using a commercial kit (Sigma-Aldrich, Saint 
Louis, MO, USA, cat.#387A). Images were acquired using a Zeiss Axiovert 35 microscope 
equipped with a digital camera (Carl Zeiss, Thronwood, NY, USA). mRNA was isolated 
from parallel cultures and gene expression was measured by qPCR (Applied Biosystems, 
Foster City, CA, USA).
4.2 RNA extraction and qPCR
Total RNA was isolated using TRIzol (Invitrogen, Grand Island, NY, USA), as published 
(Davis et al., 2017; Pacheco-Costa et al., 2014). Reverse transcription was performed using a 
high-capacity cDNA kit (Applied Biosystems, Foster City, CA, USA). qPCR was performed 
using the Gene Expression Assay Mix TaqMan Universal Master Mix with an ABI 7900HT 
real-time PCR system. The house-keeping gene glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) was used. Primers and probes were commercially available (Applied Biosystems, 
Foster City, CA, USA) or were designed using the Assay Design Center (Roche Applied 
Science, Indianapolis, IN, USA). Relative expression was calculated using the ΔCt method 
(Livak & Schmittgen, 2001).
4.3 Mice and treatment
4- (young, n=10) and 15-month-old mice (middle-aged, n=10) C57BL/6 female mice were 
obtained from National Institute on Aging (NIA) and received daily intraperitoneal injection 
of veh (1.7% DMSO) or 100μg/day (young mice) and 110μg/day (middle-aged mice) of AZ 
(DC Chemicals, Shanghai, P.R., China, cat.# DC8338), to account for body weight 
differences, for 28 days. We chose these 2 ages to determine the effect of RAGE inhibition 
at the age in which the mice reach peak bone mass (4 months of age), and later in life (15-
months of age), in which we showed there is already a significant deterioration, without 
reaching very low levels of bone mass and strength that might be difficult to reverse (Davis 
et al., 2018). Mice were assigned an ID number and the age/treatment were recorded in a 
database. Investigators performing endpoint measurements were only given the mouse ID. 
Mice were randomized and assigned to each experimental group based on spinal BMD. 
Mice (4–5/cage) were fed a regular diet (Envigo, Indianapolis, IN) and water ad libitum, and 
maintained on a 12h light/dark cycle. Animals were sacrificed between 3–5 hours after last 
injection. All experiments were carried out as planned. No mortality was recorded 
throughout the experiment, although 2 old mice exhibited signs of infections near the 
injection sites. In addition, AZ administration induced splenomegaly (Fig. S5), but no other 
signs of distress were recorded. Young mice received IP injections of calcein (30 mg/kg; 
Sigma-Aldrich, Saint Louis, MO, USA) and alizarin red (50 mg/kg; Sigma) 7 and 2 days 
before sacrifice, respectively and aged mice received IP injections of calcein (30 mg/kg; 
Sigma-Aldrich, Saint Louis, MO, USA) and alizarin red (50 mg/kg; Sigma) 10 and 3 days 
before sacrifice, respectively, to allow for dynamic histomorphometric measurements (Davis 
et al., 2018). The longer duration between labels in aged mice was done to help facilitate the 
differentiation of the two labels given the slower bone formation rate.
4.4 Bone histomorphometry
Femora and lumbar vertebrae (L1–L3) were dissected and fixed in 10% neutral buffered 
formalin as previously published (Davis et al., 2018). Static histomorphometric analysis was 
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performed on the cancellous surface of sequential methyl methacrylate embedded lumbar 
vertebrae sections stained with von Kossa/McNeal [osteoblasts] and TRAPase/Toludine blue 
[osteoclasts]. Additionally, osteoclasts were quantified on the endocortical surface paraffin 
embedded TRAPase/Toludine blue stained femur cortical bone cross-sections. Dynamic 
histomorphometric measurements were performed in unstained plastic embedded femoral 
mid-diaphysis and lumbar vertebrae bone sections (Pacheco-Costa et al., 2014). 
Histomorphometric analysis was performed using OsteoMeasure high-resolution digital 
video system (OsteoMetrics Inc., Decatur, GA, USA) (Davis et al., 2018). The terminology 
and units used are those recommended by the Histomorphometry Nomenclature Committee 
of the American Society for Bone and Mineral Research (Dempster et al., 2013).
4.5 Serum biochemistry
Blood was collected by cheek bleeding after 3 h of fasting. Plasma was separated, aliquoted, 
and stored at − 80 °C (Pacheco-Costa et al., 2015). N-terminal propeptide of type I 
procollagen (P1NP) (Immunodiagnostic Systems Inc., Fountain Hill, AZ, USA, 
cat.#AC-33F1) and C-telopeptide fragments (CTX) (RatLaps, Immunodiagnostic Systems 
Inc., Fountain Hill, AZ, USA, cat.#AC-06F1) were measured as previously published (Davis 
et al., 2018).
4.6 Osteoblast mineralization assay
Adherent-BMCs were cultured for 10 days in α-MEM supplemented with 10% FBS and 1% 
penicillin/streptomycin in the presence of 50 μM ascorbic acid and 10 mM β-glycerol 
phosphate, as previously described (Posritong et al., 2018). Cells were fixed with 3.7% 
paraformaldehyde in PBS for 1 hour, rinsed twice with distilled water, and stained for 10 
min with 40 mM Alizarin Red S (pH 4.2) at room temperature under shaking. Cells were 
then washed 5 times with water, followed by a 15 min-wash with PBS. Alizarin Red S was 
extracted by adding 1% cetylpyridinium chloride for 15 min at room temperature with 
shaking. OD was measured at 490 nm.
4.7 Apoptosis
Osteocyte apoptosis was detected in paraffin-embedded femur cross-sections using 
previously published protocols (Bivi et al., 2012). Briefly, femora were deparaffinized, 
treated with 3% H2O2 to inhibit endogenous peroxidase activity, blocked and then incubated 
with rabbit monoclonal anti-active caspase-3 antibody (1:75; Thermo Fisher Scientific In., 
Rockford, IL, USA, cat.#PA5–23921) (Delgado-Calle et al., 2016). Sections were then 
incubated with anti-rabbit biotinylated secondary antibody followed by avidin conjugated 
peroxidase (Vectastain Elite ABC Kit; Vector Laboratories Inc., Burlingame, CA, USA). 
Color was developed with a diaminobenzidine substrate chromogen system (Acros Organics, 
New Jersey, USA). Cells expressing the protein of interest are stained in brown, whereas 
negative cells are green-blue. Nonimmune IgG was used as negative control.
4.8 Ex vivo bone organ cultures
Long bones were isolated from 4- and 16-month-old female C57BL/6 mice and BMCs were 
flushed out with α-MEM. Osteocyte-enriched marrow-flushed long bones were cultured ex 
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vivo in α-MEM supplemented with 10% FBS and 1% P/S with veh or AZ (100ng/mL) and 
cultured for 24 hours. Following treatment, bones were collected, frozen in liquid nitrogen, 
and stored at − 80 °C. Gene expression was measured by qPCR (Applied Biosystems, Foster 
City, CA, USA).
4.9 Bone mineral density (BMD) and body composition (fat and lean mass) by dual 
energy x-ray absorptiometry (DXA)
Bone mineral density (BMD) and body composition were measured monthly by dual X-ray 
absorptiometry (DXA) using a PIXImus densitometer (G.E. Medical Systems, Lunar 
Division, Madison, WI, USA) (Zhang et al., 2011). BMD measurements included total BMD 
(excluding the head and tail), entire femur (femoral BMD) and L1–L6 vertebra (spinal 
BMD) (Davis et al., 2018). Body composition included body weight, fat mass, and lean 
mass. Calibration was performed before scanning with a standard phantom, as recommended 
by the manufacturer.
4.10 Micro-computed tomography (μCT) analysis
Femora and L4 vertebrae were dissected, wrapped in saline-soaked gauze and frozen at 
− 20 °C (Davis et al., 2018). Vertebra and femora, 6 bones per scan, were scanned using a 
65kV source, 0.5mm Al filter, 0.7 degree rotation and two-image averaging with an isotropic 
voxel size of 9μm using a SkyScan 1176 system (SkyScan, Kontich, Belgium). Scans were 
reconstructed and analyzed using manufacturer software. Nomenclature is reported in 
accordance with the guidelines for μCT (Bouxsein et al., 2010).
4.11 Biomechanical testing
Femoral three-point bending testing was performed following previously published 
protocols (Davis et al., 2018). Structural mechanical properties, ultimate load, stiffness, 
displacement and work were determined from the load–deformation curves using standard 
definitions while material-level estimations of properties were calculated using standard 
equations. Cross-sectional moment of inertia and anterior–posterior diameter were 
determined by μCT and were used to calculate material-level properties, as previously 
described (Davis et al., 2018).
4.12 Muscle weight
Skeletal muscles gastrocnemius, tibialis anterior, quadriceps and soleus, were harvested and 
weighed immediately following dissection. Muscle weight was corrected by total body 
weight and reported as the percentage of muscle per body weight. After weighing, muscles 
were snap frozen and store at −80°C until used for gene expression analysis.
4.13 Muscle histology and morphometric analysis
The forearms of mice were removed and fixed in 10% neutral buffered formalin. Forearms 
were cross-sectioned, demineralized and embedded in paraffin and then sectioned on a 
microtome. Tissue morphology was assessed on 4 μm–thick cross-sections of muscles 
sections stained with hematoxylin and eosin (H&E) dye. Myofiber cross-sectional area 
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(CSA) was analyzed on H&E-stained forearm muscle section images using image J analysis 
software and tablet input device (Bonetto, Rupert, Barreto, & Zimmers, 2016).
4.14 C2C12 cell culture and myotube diameter measurement
C2C12 myoblasts were grown and seeded onto 12-well plates (7,500 cells/cm2). The cells 
were then exposed to DMEM supplemented with horse serum for five days, then 
subsequently treated for 48 hrs with 5% serum from young or aged animals treated with veh 
or AZ. Myotubes were fixed using chilled acetone/methanol (1:1) and washed with PBS, 
stained using a primary antibody against myosin heavy chain (#MF-20, Developmental 
Studies Hybridoma Bank, Iowa City, IA) overnight at 4°C, then stained with Alexaflour 594-
labeled secondary antibody (Invitrogen, Grand Island, NY) at room temperature for one 
hour. Myotubes were imaged using an Axio Observer.Z1 motorized microscope (Zeiss, 
Oberchoken, Germany). Average myotube diameter was measured per field of view using 
Image J analysis software (Schneider, Rasband, & Eliceiri, 2012) and a Cintiq pen tablet 
input device (Wacom, Vancouver, WA).
4.15 Western blot analysis
Ubiquitin-conjugated protein levels were evaluated in protein lysates isolated from the 
quadriceps of young and aged veh- and AZ-treated mice. Protein lysates were separated on 
10% SDS–PAGE gels (BioRad) and electrotransferred to nitrocellulose membranes 
(Millipore, Billerica, MA, USA). Membranes were then incubated in blocking solution 
(SEABlock) for 60 min and probed with primary antibodies diluted 1:1000 in SeaBLOCK 
+ 0.2% Tween against a monoclonal anti-Ubiqutin (#3933, Cell Signaling Technologies, 
Danvers, MA) overnight at 4 °C, followed by corresponding secondary fluorescent 
antibodies diluted 1:10,000 in SEABlock + 0.2% Tween for 1 h at room temperature. After 
rinsing with PBS-T, the membranes were developed using LICOR imaging. Bands were 
detected using an Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, 
USA), and their intensity was quantified using ImageJ.
4.16 Statistical analysis
Data were analyzed by using SigmaPlot (Systat Software Inc., San Jose, CA, USA). All 
values are reported as the mean ± standard deviation. Differences were evaluated either by 
two-way ANOVA with post-hoc analysis using Tukey Method or by Student’s t-test, as 
appropriate. Differences were considered significant when p<0.05.
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1. Short-term RAGE inhibition with Azeliragon attenuated the aging-related 
body composition changes in fat and lean mass.
2. Azeliragon administration reversed the skeletal muscle alterations induced in 
early aging
3. Azeliragon did not prevent the aging-induced alterations in bone geometry or 
mechanics, likely due to its differential effects [direct vs. indirect] on bone 
cell viability/function.
4. Aging differentially altered glut transporter and metabolic enzyme expression 
in bone and skeletal muscle.
5. Azeliragon treatment had differential effects on bone and skeletal muscle in 
middle-aged mice.
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Figure 1. AZ suppresses osteoclast differentiation in vitro.
A) Illustration of AZ mechanism of action. B) Mature osteoclasts/well generated in vitro 
from non-adherent BMCs from young and middle-aged WT female mice (n=6). 
Representative images are shown, scale bar indicates 50μm.
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Figure 2. Short-term AZ treatment has modest effects on osteoclasts in vivo.
A) Illustration of in vivo experimental design. Osteoclasts on B) femoral cortical mid-
diaphysis and C) vertebral cancellous TRAP/T.blue stained sections (n=8–9). Representative 
images are shown (black arrows point at osteoclasts), scale bar indicates 25μm. D) 
Osteoclast-related gene mRNA expression in whole tibia samples isolated from young and 
aged vehicle- and Azeliragon-treated mice (n=8–10). Bars represent mean±SD, black line: 
p<0.05, for the overall age effect and *p<0.05, vs veh-treated mice at the same age by two-
way ANOVA, Tukey.
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Figure 3. Short-term AZ treatment attenuates osteoblast differentiation/activity in vivo.
A) Osteoblasts on von Kossa/McNeal stained vertebra sections (n=7–10). Representative 
images are shown, scale bar indicates 25μm. B) Circulating serum PINP levels in young and 
aged veh- and AZ-treated mice (n=8–10). C) mRNA expression of osteoblast-related genes 
in whole tibia samples isolated from young and aged vehicle- and Azeliragon-treated 
mice(n=8–10). D) Dynamic histomorphometric parameters in unstained vertebra sections 
(n=8–10). E) Mineral apposition rate (MAR), mineralizing surface (MS)/BS, and bone 
formation rate (BFR)/BS measured in unstained sections of the femoral mid-diaphysis from 
young and aged vehicle- and Azeliragon-treated mice (n=8–10). F) Mineralization assay of 
primary osteoblasts generated in vitro from adherent-BMCs from young and middle-aged 
WT mice (n=5). Bars represent mean±SD, black line: p<0.05, for the overall age effect and 
*p<0.05, vs veh-treated mice at the same age by two-way ANOVA, Tukey.
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Figure 4. Systemic RAGE inhibition with AZ treatment increases osteocyte apoptosis and pro-
inflammatory cytokine production.
A) Active-caspase3 positive apoptotic osteocytes and number of empty lacunae scored in 
active caspase3 stained bone sections (n=8–10). Representative images of active caspase3-
positive osteocytes (arrow, black), scale bar indicates 10μm. B) Osteocytic gene and C) 
cytokine mRNA levels in tibia from young and middle-aged veh and AZ-treated mice (n=7–
10). D) Illustration of bone organ culture experimental design. mRNA expression of E) 
apoptosis-associated and F) pro-inflammatory cytokines in marrow-flushed bone cultures 
(n=3–5). Bars represent mean±SD, black line: p<0.05, for the overall age effect and 
*p<0.05, vs veh-treated mice at the same age by two-way ANOVA, Tukey.
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Figure 5. Short-term AZ treatment decreases bone mass accrual, but not bone architecture in 
young or old mice.
A) BMD of young and middle-aged mice following veh- or AZ-treatment (n=8–10). 
Cancellous microarchitecture evaluated by μCT in the B) L4 vertebra and C) distal femur 
(n=8–9). Representative images are shown. D) Cortical bone geometry evaluated by μCT in 
the femoral mid-diaphysis (n=8–9). Representative images are shown. Bars represent mean
±SD, black line: p<0.05, for the overall age effect and *p<0.05, vs veh-treated mice at the 
same age by two-way ANOVA, Tukey.
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Figure 6. AZ treatment reverses the loss of skeletal muscle mass induced with aging.
A) Body weight, B) fat and lean mass indicated as percentage of body weight (n=8–10), C) 
muscle weights (n=8–9), D) myogenesis and satellite cell marker mRNA expression in 
tibialis anterior muscle (n=7–9) of young and middle-aged mice. Bars represent mean±SD, 
black line: p<0.05, for the overall age effect and *p<0.05, vs veh-treated mice at the same 
age by two-way ANOVA, Tukey.
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Figure 7. AZ treatment partially improves the cellular processes involved in maintaining skeletal 
muscle homeostasis in aging.
A) low- and high-magnification images of forearm muscle cross-sections, muscle of interest 
is circled in black, scale bar indicates 50μm, and B) average myofiber cross-sectional area 
(CSA) (n=6–8). C) Average myotube diameter per field and D) distribution of myotube 
diameter of serum-treated C2C12 cells (n=10). Representative images are shown, scale bar 
indicates 50μm. E) Ubiquitin-conjugated and GAPDH protein patterns in skeletal muscle 
(n=6). F) mRNA levels of atrophy-related genes in tibialis anterior muscle (n=7–9). Bars 
represent mean±SD, black line: p<0.05, for the overall age effect and *p<0.05, vs veh-
treated mice at the same age by two-way ANOVA, Tukey.
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Figure 8. Systemic inhibition of RAGE signaling reverses the aging-induced metabolic alterations 
in skeletal muscle, but not in bone.
Glucose transporter GLUT1–4, and glycolytic and oxidative enzyme mRNA levels in tibialis 
anterior muscle (A-C) and in tibia (D-F) (n=7–9). Bars represent mean±SD, black line: 
p<0.05, for the overall age effect and *p<0.05, vs veh-treated mice at the same age by two-
way ANOVA, Tukey.
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